Curriculum Vitae

Sherif S. Iskander, MD, FACC
1783 Troup Hwy, Tyler, Texas 75701
Office (903)-595-2283 Fax (903)-597-2238

Practice

2009 - Present	Tyler Cardiac and Endovascular Center - 1769 Troup Hwy, Tyler, Texas
2001- Present	Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Affiliation

2001-Present	CAET - Research - 1761 Troup Hwy, Tyler, Texas
1/1/13-4/26/13	TAD Clinical Research - 1741 Troup Hwy, Tyler, Texas

Education

Post-Graduate Education and Experience

2002	Advances in Vascular Diagnostics Symposium
2002	Faces of CAD Speaker Training Meeting II - Santa Barbara, California
2001-Present	Director of Nuclear cardiology laboratory, Invasive cardiologist Cardiovascular Associates of East Texas - Tyler, TX
5/2001	Faces of CAD Speaker Training Meeting I - Las Vegas, Nevada
1999-2000	Nuclear Cardiology Fellowship, The Methodist Hospital, Baylor College of Medicine
1999	Safe Use of Radioactive Materials in Medical Imaging for nuclear license certification
1998-2001	Cardiology Fellowship, Baylor College of Medicine Affiliated Hospitals - Houston, TX
1995-1998	Internal Medicine Residency, Hahnemann University - Philadelphia, PA
1994-1995	Transitional Year New York Hospital Medical Center of Queens Flushing - New York
1992-1994	Internal Medicine, Summit Medical Center - Union City, New Jersey
1991-1992	Family Practitioner, Public Medical Center, Moharem Bek - Alexandria, Egypt
1990-1991	Internship Rotation, Alexandria University Hospital - Alexandria, Egypt
1977-1980	High School - Alexandria, Egypt GSECE – General Secondary Education Certificate, Victory College

Academic Degrees

Premedical Education
Alexandria University - Alexandria, Egypt

Faculty of Science

MD Degree
Alexandria University - Alexandria, Egypt
Faculty of Medicine

Board Certification

Cardiovascular Disease Board Certification

Nuclear Cardiology Board Certification

Internal Medicine Board Certification

Education Commission for Foreign Medical Graduate (ECFMG)

Licensure

2000	Nuclear Cardiology
1999	Texas State Board of Medical Examiners
1995	Pennsylvania State License
1991	Egyptian Medicine and Surgery License

Hospital Appointments

CHRISTUS Trinity Mother Frances Hospital, Tyler, Texas

CHRISTUS Trinity Mother Frances Hospital, Jacksonville, Texas

UT Health East Texas (ETMC), Tyler, Texas

UT Health East Texas (ETMC), Athens, Texas

UT Health East Texas (ETMC), Carthage, Texas

UT Health East Texas (ETMC), Jacksonville, Texas

Baylor Scott & White Texas Spine and Joint Hospital, Tyler, Texas

Research

Principal Investigator - FORXIGA-HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. (D1699C00001)

Co-Investigator - PROVE-HF - A 52 Week, open label evaluation on the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction.

Co-Investigator - CHAMP-HF – Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.

Co-Investigator – GLORIA –AF - Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation
Co-Investigator – ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator – SUMMIT - HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator – DECLARE **-** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator – ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.
Co-Investigator – AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator – EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID - A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Co-Investigator – RESOLUTE US - A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm
Co-Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Primary Investigator – VISION 305 Study - "Vasodilator Induced Stress In Concordance with Adenosine" A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-

controlled, complete two-arm crossover study with a reference third arm.

Co-Investigator – RE-LY Study - **R**andomized **E**valuation of **L**ong term anticoagulant therap**y** (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.

Primary Investigator – ACCOMPLISH - A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.

Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.

Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator - APEX-AMI Study - "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention." (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.

Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST- segment elevation.

Assessment of myocardial viability early after acute myocardial infarction by nitroglycerin-augmented Tc-99m sestamibi SPECT: Its role in predicting improvement of segmental and global ventricular function after revascularization. (ongoing)

Tetrofosmin myocardial perfusion imaging early and six months after percutaneous transluminal coronary angioplasty (PTCA) with and without stenting: A prospective study. (ongoing)

Principal Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System

Principal investigator: INSPIRE: THE ADENOSINE SESTAMIBI SPECT POST INFARCTION EVALUATION TRIAL. A Randomized, Prospective Multicenter Trial Evaluating the Role of Adenosine Tc-99m Sestamibi Single - Photon Emission Computed Tomography for Assessing Risk and Therapeutic Outcomes in Survivors of Acute Myocardial Infarction.

Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532

Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone• I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US

Co-Investigator – REPLACE II – A Randomized Evaluation in PCI Linking Angiomax to Reduce Clinical Events, Part 2: REPLACE – 2 (TMC-BIV-01-03)

Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II Clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.

Co-Investigator – Otuska Protocol 21-98-214-01 CASTLE A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Assess The Long-Term Effects of Pletal• (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease

Co-Investigator - IMPROVE IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

Co-Investigator - TRACER "A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome"

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes

Co-Investigator - TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Co-Investigator - ENDEAVOR SVS Registry: "A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single *De novo* Lesions in Small Diameter Native Coronary Arteries"

Co-Investigator - Taxus Libertē "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen"

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.